Trial Profile
Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in the Management of Peripheral Neuropathic Pain ; Early Phase II, Multi-center, Randomized, and Semi-double Blind Controlled Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 May 2017
Price :
$35
*
At a glance
- Drugs Capsaicin (Primary)
- Indications Diabetic nephropathies; Peripheral neuropathies; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Samyang Biopharmaceuticals Corporation
- 03 Sep 2014 New trial record